Expansion leverage TriLink is rapidly expanding its manufacturing footprint with a new GMP enzyme facility in Jupiter, Florida, creating opportunities to source and scale RNA therapeutics ingredients locally for customers in North America and beyond.

Partnership potential Ongoing collaborations and MOUs with IVI, Aldevron, Tebubio, and Avantor indicate a strong ecosystem approach; this opens doors for joint development programs, co-marketing, and accelerated access to CleanCap mRNA capping tech and nucleic acid supplies in various regions.

Capable technology TriLink’s patented CleanCap mRNA capping technology and ready-made/made-to-order nucleic acid solutions position it as a strategic supplier for vaccine and therapeutic programs, appealing to customers seeking quality, reliability, and speed.

Global reach With a global leadership position in nucleic acid and mRNA solutions and European/EMEA expansion via Avantor partnerships, TriLink can support multinational programs requiring consistent supply across regions.

Strategic funding signals Revenue range ($100M-$250M) and a focus on scalable, high-value RNA solutions indicate potential upsell of premium mRNA kits, CDMO services, and bulk raw materials to established biotech and pharmaceutical customers pursuing rapid development timelines.